

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell

New England Journal of Medicine

385, 683-694

DOI: [10.1056/nejmoa2106391](https://doi.org/10.1056/nejmoa2106391)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Adjuvant pembrolizumab shows promise. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 604-604.	12.5	0
2	The Promise of Adjuvant Immunotherapy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 756-758.	13.9	13
3	Late metastatic recurrence of renal cell carcinoma in the heart and mediastinum: A case report and review of literature. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100119.	0.1	1
4	Advances in immuno-oncology and precision oncology: Where are we heading?. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 6, 109-110.	0.0	0
5	Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. <i>European Urology Oncology</i> , 2022, 5, 265-267.	2.6	6
6	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. <i>Cancers</i> , 2021, 13, 5065.	1.7	13
7	Pathogenic mitochondrial dysfunction and metabolic abnormalities. <i>Biochemical Pharmacology</i> , 2021, 193, 114809.	2.0	21
8	Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 778459.	2.2	6
9	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
10	Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. <i>Kidney Cancer</i> , 2021, 5, 167-179.	0.2	1
11	Adjuvant immunotherapy for NSCLC “ does treating earlier mean treating better?. <i>Nature Reviews Clinical Oncology</i> , 2021, , .	12.5	1
12	Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 8891-8898.	1.3	2
13	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. <i>Cancers</i> , 2021, 13, 5548.	1.7	11
14	Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>N Engl J Med</i> 2021;385:683-694. <i>European Urology</i> , 2021, 81, e28-e28.	0.9	4
15	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
16	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 1919-1920.	13.9	9
17	Adjuvant Therapy After Surgical Resection of Nonmetastatic Renal Cell Carcinoma: One Size Does Not Fit All. <i>European Urology</i> , 2022, 81, 432-433.	0.9	3
18	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	2.2	17

#	ARTICLE	IF	CITATIONS
20	Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?. Expert Opinion on Investigational Drugs, 2021, , 1-9.	1.9	4
22	Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?. Future Oncology, 2022, 18, 519-522.	1.1	0
23	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. European Urology, 2022, 81, 414-425.	0.9	40
24	Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clinical Genitourinary Cancer, 2022, , .	0.9	3
25	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. European Urology Oncology, 2022, 5, 120-124.	2.6	6
26	KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma. Indian Journal of Urology, 2022, 38, 75.	0.2	6
27	Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers, 2022, 14, 239.	1.7	12
29	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. European Urology, 2022, 81, 134-137.	0.9	29
30	Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer. Human Vaccines and Immunotherapeutics, 2022, 18, 1-8.	1.4	11
31	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. World Journal of Urology, 2022, 40, 1489-1496.	1.2	3
32	C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. International Journal of Clinical Oncology, 2022, 27, 969-976.	1.0	2
33	Adjuvant pembrolizumab in renal cell carcinoma. Cancer Research Statistics and Treatment, 2022, 5, 191.	0.1	0
34	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. European Urology, 2022, 81, 570-573.	0.9	22
35	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 2022, 40, 1772-1782.	0.8	9
36	Recent pharmacological approaches for the treatment of renal cell carcinoma. Expert Review of Clinical Pharmacology, 2022, 15, 187-195.	1.3	1
37	Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. World Journal of Urology, 2022, 40, 1175-1183.	1.2	5
38	Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities. European Urology, 2022, 81, 574-575.	0.9	7
39	Kidney Cancer Research Highlights from ASCO GU 2022 Meeting. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2022, 20, 30-32.	0.1	0

#	ARTICLE	IF	CITATIONS
40	The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2022, 34, 234-242.	1.1	16
41	Patient-Derived Renal Cell Carcinoma Xenografts Capture Tumor Genetic Profiles and Aggressive Behaviors. <i>Kidney Cancer</i> , 2022, 6, 11-22.	0.2	0
42	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>European Urology</i> , 2022, 82, 399-410.	0.9	485
43	Recent Advances in Medical Therapy for Urological Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 746922.	1.3	8
44	Variability in prognostic models for localized renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, , .	1.9	0
45	First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. <i>Cancer Treatment Reviews</i> , 2022, 105, 102374.	3.4	7
46	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
47	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. <i>Frontiers in Oncology</i> , 2022, 12, 871252.	1.3	8
48	Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers. <i>ESMO Open</i> , 2022, 7, 100432.	2.0	0
49	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. <i>Academic Radiology</i> , 2022, 29, 1869-1884.	1.3	3
50	Prognostic Significance of NLR About NETosis and Lymphocytes Perturbations in Localized Renal Cell Carcinoma With Tumor Thrombus. <i>Frontiers in Oncology</i> , 2021, 11, 771545.	1.3	10
51	A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 178.	1.7	2
52	New milestones for IOTTECH in 2022. <i>Immuno-Oncology Technology</i> , 2021, 12, 100060.	0.2	0
53	DNA Methylation in INA, NHLH2, and THBS4 Is Associated with Metastatic Disease in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 39.	1.7	4
54	Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. <i>Cancers</i> , 2022, 14, 2049.	1.7	7
55	Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma. <i>International Cancer Conference Journal</i> , 2022, 11, 205-209.	0.2	2
56	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
57	Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 871217.	2.2	7

#	ARTICLE	IF	CITATIONS
58	Immunotherapy and Checkpoint Inhibitors in Urologic Cancer. <i>Urologic Clinics of North America</i> , 2022, 49, 323-334.	0.8	0
59	Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2022, 168, 68-76.	1.3	0
60	The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 790381.	1.3	5
61	Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution. <i>Cancer Treatment and Research</i> , 2022, 183, 201-223.	0.2	0
62	Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. <i>Future Medicinal Chemistry</i> , 2022, , .	1.1	0
63	Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab. <i>Seminars in Oncology</i> , 2022, , .	0.8	2
64	Practice-changing publications: Kidney cancer. <i>Canadian Urological Association Journal</i> , 2021, 16, E237-9.	0.3	0
65	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 565-574.	1.1	1
66	Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma. <i>Frontiers in Urology</i> , 2022, 2, .	0.2	1
67	Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5448.	1.8	4
68	Developments in personalized therapy for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 647-655.	1.1	6
69	Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 347.e1-347.e8.	0.8	1
70	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 391-418.	1.9	20
71	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	1.7	4
72	Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103706.	2.0	3
73	Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?. <i>Cells</i> , 2022, 11, 1658.	1.8	6
74	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 311-326.	1.8	3
75	The Four-Feature Prognostic Models for Cancer-Specific and Overall Survival after Surgery for Localized Clear Cell Renal Cancer: Is There a Place for Inflammatory Markers?. <i>Biomedicines</i> , 2022, 10, 1202.	1.4	3

#	ARTICLE	IF	CITATIONS
77	Editorial Comment from Dr Ishihara <i>et al.</i> to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese high-volume center. <i>International Journal of Urology</i> , 2022, 29, 993-994.	0.5	0
78	Rapid Profiling of Tumor-Immune Interaction Using Acoustically Assembled Patient-Derived Cell Clusters. <i>Advanced Science</i> , 2022, 9, .	5.6	21
79	Nanomedicine for urologic cancers: diagnosis and management. <i>Seminars in Cancer Biology</i> , 2022, 86, 463-475.	4.3	3
80	Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 189-203.	1.8	7
81	Future treatment options in metastatic clear cell renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S47-2S58.	0.6	0
82	How to Treat Renal Cell Carcinoma. <i>JACC: CardioOncology</i> , 2022, 4, 271-275.	1.7	3
83	Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. <i>JAMA Network Open</i> , 2022, 5, e2216058.	2.8	9
84	Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear-cell renal cell carcinoma treated with radical or partial nephrectomy. <i>International Journal of Urology</i> , 2022, 29, 1235-1237.	0.5	1
85	Re: Björje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2022.03.006 . <i>European Urology</i> , 2022, 82, e88.	0.9	1
86	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
87	What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy. <i>Kidney Cancer</i> , 2022, 6, 95-103.	0.2	1
88	Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?. <i>Bulletin Du Cancer</i> , 2022, , .	0.6	0
89	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. <i>Immunotherapy</i> , 0, , .	1.0	8
90	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2957-2995.	0.8	97
91	Contemporary techniques and outcomes of surgery for locally advanced renal cell carcinoma with focus on inferior vena cava thrombectomy: The value of a multidisciplinary team. <i>Asian Journal of Urology</i> , 2022, , .	0.5	0
92	Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma. <i>Case Reports in Urology</i> , 2022, 2022, 1-5.	0.1	0
93	Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	0
94	De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 55-63.	1.3	8

#	ARTICLE	IF	CITATIONS
96	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
97	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. <i>Journal of Personalized Medicine</i> , 2022, 12, 1073.	1.1	36
98	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	7.7	7
100	Reply to Yongbao Wei, Ruochen Zhang, and Le Lin's Letter to the Editor re: Björje Ljungberg, Laurence Albiges, Yasmin Abu-Chanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>Eur Urol.</i> 2022;82:e88. <i>European Urology</i> , 2022, 82, e111-e112.	0.9	7
101	Immune checkpoint inhibitors and kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 449-455.	1.0	3
102	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
103	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 800-807.e1.	2.3	5
104	Oncological safety of partial nephrectomy for pT3a renal cell carcinoma: reading between the lines. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	2
105	Re: Lymph Node Colonization Induces Tumor-immune Tolerance To Promote Distant Metastasis. <i>European Urology</i> , 2022, , .	0.9	2
106	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
107	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
108	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	3.2	8
109	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches. <i>Cancer Treatment Reviews</i> , 2022, 109, 102437.	3.4	3
110	Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1153-1168.	1.3	7
111	KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC. , 0, , .		0
112	The multispeciality approach to the management of localised kidney cancer. <i>Lancet, The</i> , 2022, 400, 523-534.	6.3	16
113	Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 191-207.	0.5	1
114	Deep Learning-Based Methods for Directing the Management of Renal Cancer Using CT Scan and Clinical Information. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
115	Disparities in Clinical Care and Research in Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022, 6, 147-157.	0.2	1
116	Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. <i>Current Oncology</i> , 2022, 29, 5426-5441.	0.9	5
117	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
118	Role of metastasectomy in the management of renal cell carcinoma. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
119	New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future. <i>Cancers</i> , 2022, 14, 3616.	1.7	16
121	Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2023, 6, 323-330.	2.6	17
122	Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	1
123	A Causal Framework for Making Individualized Treatment Decisions in Oncology. <i>Cancers</i> , 2022, 14, 3923.	1.7	9
124	Subphenotypes in acute kidney injury: a narrative review. <i>Critical Care</i> , 2022, 26, .	2.5	27
125	Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3754.	1.7	10
126	Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinomaâ€”Future or the Past?. <i>Cancers</i> , 2022, 14, 3777.	1.7	6
127	Identifying patients for adjuvant therapy after nephrectomy. <i>Lancet, The</i> , 2022, 400, 1080-1081.	6.3	4
128	Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IBâ€”IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 1274-1286.	5.1	202
129	Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro. <i>European Urology Open Science</i> , 2022, 44, 92-93.	0.2	0
130	The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2022, 33, 100640.	0.7	7
131	The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211227.	1.4	7
132	Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. <i>Cancers</i> , 2022, 14, 4142.	1.7	3
134	How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?. <i>World Journal of Urology</i> , 2022, 40, 2667-2673.	1.2	3

#	ARTICLE	IF	CITATIONS
135	Editorial Comment to Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear cell renal cell carcinoma treated with radical or partial nephrectomy. <i>International Journal of Urology</i> , 2022, 29, 1237-1238.	0.5	0
137	Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: A meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30830.	0.4	0
138	Adjuvant therapy for renal cell carcinoma, finally a new standard?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
139	Editorial: Optimizing surgical procedures in renal cancers to improve patient outcomes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
140	The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. <i>European Urology Focus</i> , 2023, 9, 114-124.	1.6	5
141	What Surgeons Need to Know About Gene Therapy for Cancer. <i>Advances in Surgery</i> , 2022, 56, 151-168.	0.6	1
142	Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 495.e11-495.e17.	0.8	2
144	Reply to U. Capitanio et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
145	Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4607.	1.7	2
146	Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. <i>Acta Oncologica</i> , 2022, 61, 1268-1277.	0.8	2
148	Predicting the Risk of Progression in Patients With Kidney Cancer: Aiming at the Optimal Tool in the Optimal Setting. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	1
149	Personalizing immunotherapy for renal cell carcinoma: how far have we come?. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-5.	1.4	2
150	Identification of a Novel Renal Metastasis Associated CpG-Based DNA Methylation Signature (RMAMS). <i>International Journal of Molecular Sciences</i> , 2022, 23, 11190.	1.8	2
151	Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1133-1144.	5.1	122
152	Adjuvant immunotherapy for renal cell carcinoma. <i>Lancet Oncology</i> , The, 2022, 23, 1110-1111.	5.1	4
153	Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 400, 1103-1116.	6.3	98
154	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
155	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life. <i>European Journal of Cancer</i> , 2022, 176, 88-99.	1.3	18

#	ARTICLE	IF	CITATIONS
156	Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. <i>Nature Communications</i> , 2022, 13, .	5.8	4
157	The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis. <i>Cancers</i> , 2022, 14, 5258.	1.7	1
158	The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma. <i>European Urology</i> , 2023, 83, 10-14.	0.9	23
160	Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12634.	1.8	0
161	You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?. <i>Journal of Clinical Oncology</i> , 2022, 40, 4044-4047.	0.8	5
162	Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. <i>Cancer Management and Research</i> , 0, Volume 14, 3071-3081.	0.9	2
163	Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma. <i>IScience</i> , 2022, 25, 105389.	1.9	3
164	Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma. <i>Lancet Oncology</i> , The, 2022, 23, e487.	5.1	0
165	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
166	Epigenetics in advanced renal cell carcinoma: Potential new targets. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103857.	2.0	2
167	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. <i>International Immunopharmacology</i> , 2022, 113, 109365.	1.7	6
168	Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?. <i>European Urology Open Science</i> , 2022, 46, 39-42.	0.2	5
169	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
170	Hot topics in renal cancer pathology: implications for clinical management. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1275-1287.	1.1	4
171	Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 2926.	1.4	7
172	Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	1
173	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
174	Adjuvant therapy options in renal cell carcinoma – targeting the metastatic cascade. <i>Nature Reviews Urology</i> , 2023, 20, 179-193.	1.9	4

#	ARTICLE	IF	CITATIONS
175	Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis. , 2022, 1, 293-304.		0
176	Cryoablation for the Treatment of Kidney Cancer: Comparison With Other Treatment Modalities and Review of Current Treatment. Cureus, 2022, , .	0.2	0
177	French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progres En Urologie, 2022, 32, 1195-1274.	0.3	11
178	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. Frontiers in Pharmacology, 0, 13, .	1.6	1
179	Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer. Cancer Medicine, 0, , .	1.3	1
180	In the literature: November 2022. ESMO Open, 2022, 7, 100643.	2.0	0
181	Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. Critical Reviews in Oncology/Hematology, 2023, 181, 103881.	2.0	3
182	Current and Future Biomarkers in the Management of Renal Cell Carcinoma. Urologic Clinics of North America, 2023, 50, 151-159.	0.8	2
183	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development, 2022, 7, 131-149.	0.4	3
184	Therapeutic Antibodies in Cancer Treatment in the UK. International Journal of Molecular Sciences, 2022, 23, 14589.	1.8	1
185	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology, 2023, 20, 133-157.	1.9	46
186	2022 European Society for Medical Oncology: Meeting highlights. Canadian Urological Association Journal, 2022, 16, E590-6.	0.3	1
187	Can Pre-Operative Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Non-Metastatic Renal Carcinoma Recurrence after Nephrectomy? (UroCCR-61 Study). Cancers, 2022, 14, 5692.	1.7	6
188	Development and implementation of an immunotherapy unit in a urology department. Actas Urológicas Españolas (English Edition), 2022, , .	0.2	0
189	A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer. Frontiers in Oncology, 0, 12, .	1.3	6
190	High VSX1 expression promotes the aggressiveness of clear cell renal cell carcinoma by transcriptionally regulating FKBP10. Journal of Translational Medicine, 2022, 20, .	1.8	2
191	Current status and novel insights into the role of metastasectomy in the era of immunotherapy. Expert Review of Anticancer Therapy, 2023, 23, 57-66.	1.1	1
192	Renal cell carcinoma metastatic to the sinonasal cavity. ANZ Journal of Surgery, 0, , .	0.3	0

#	ARTICLE	IF	CITATIONS
193	Reactualization of sunitinib in the treatment of metastatic renal cell carcinoma. Meditsinskiy Sovet, 2022, , 65-72.	0.1	0
194	Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade. Cancers, 2022, 14, 6230.	1.7	3
195	Immune Checkpoint Inhibitor Therapy in Oncology. JACC: CardioOncology, 2022, 4, 579-597.	1.7	25
196	Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor. Kidney Cancer, 2022, 6, 201-203.	0.2	1
197	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell International, 2022, 22, .	1.8	3
198	The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 6018.	1.7	2
199	Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. Cell Death Discovery, 2022, 8, .	2.0	3
201	International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma. European Urology Oncology, 2023, 6, 76-83.	2.6	4
202	Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. International Journal of Clinical Oncology, 0, , .	1.0	0
203	Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1. , 0, , 282-290.		0
204	Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma. Lancet Oncology, The, 2023, 24, e7.	5.1	1
205	Machine learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR ¹⁵). BJU International, 2023, 132, 160-169.	1.3	6
206	The Role of Immunotherapy in Renal Cell Carcinoma. , 2023, , 1-31.		0
207	Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial. European Urology, 2023, 83, 475-475.	0.9	0
208	Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?. Immunotherapy, 0, , .	1.0	0
209	Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology and Oncology, 2023, 12, .	2.0	17
210	Editorial: Molecular genetics and therapeutic advances in renal carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
211	Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. Cancers, 2023, 15, 529.	1.7	3

#	ARTICLE	IF	CITATIONS
212	Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. <i>Hepatology International</i> , 2023, 17, 406-416.	1.9	10
213	Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?. <i>Kidney Cancer</i> , 2023, 7, 1-11.	0.2	2
214	Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors. <i>Current Oncology Reports</i> , 2023, 25, 123-129.	1.8	3
215	Proteomics Characterization of Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 384.	1.0	1
216	Immunotherapy for Urological Tumors on YouTube™: An Information-Quality Analysis. <i>Vaccines</i> , 2023, 11, 92.	2.1	4
217	Update on systemic therapy for clear cell renal cell carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
218	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. <i>Cancers</i> , 2023, 15, 665.	1.7	11
219	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
220	Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis. <i>BJU International</i> , 2023, 131, 553-561.	1.3	2
221	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. <i>OncoTargets and Therapy</i> , 0, Volume 16, 49-64.	1.0	1
222	The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 324-333.	0.9	4
223	Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review. <i>Seminars in Oncology</i> , 2022, 49, 439-455.	0.8	3
224	Benign and Malignant Renal Disease. <i>IDKD Springer Series</i> , 2023, , 153-168.	0.8	0
225	Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. <i>Cancers</i> , 2023, 15, 1433.	1.7	3
226	Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 1220-1231.	3.2	2
227	Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers. <i>Lancet</i> , The, 2023, 401, 796-798.	6.3	2
228	Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer. <i>Immunotherapy</i> , 2023, 15, 397-400.	1.0	1
229	GSH-specific fluorescent probe for sensing, bioimaging, rapid screening of natural inhibitor Celastrol and ccRCC theranostics. <i>Analytica Chimica Acta</i> , 2023, 1248, 340933.	2.6	1

#	ARTICLE	IF	CITATIONS
230	Adaptive Immunity in Genitourinary Cancers. <i>European Urology Oncology</i> , 2023, 6, 263-272.	2.6	3
231	Radiation Therapy in the Treatment of Localized and Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 325-334.	0.8	1
232	Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 206-217.	1.1	1
233	The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 285-303.	0.8	5
234	POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6849.	1.8	4
235	Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. <i>Urologic Clinics of North America</i> , 2023, 50, 261-284.	0.8	4
236	Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	2
237	Renal cell carcinoma with intracardiac tumor thrombus extension: Radical surgery yields 2 years of postoperative survival in a single-center study over a period of 30 years. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
238	Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
239	Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, , .	0.6	1
240	Geriatric assessment in the older adult with genitourinary cancer: A narrative review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
241	Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors. <i>Advances in Anatomic Pathology</i> , 2023, 30, 203-210.	2.4	0
242	CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 1001.	1.7	1
243	Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2023, 401, 821-832.	6.3	47
244	The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
245	Editorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. <i>International Journal of Urology</i> , 2023, 30, 279-280.	0.5	0
246	Regulatory implications of ctDNA in immuno-oncology for solid tumors. , 2023, 11, e005344.		10
247	Downstream Targets of VHL/HIF-1 α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. <i>Cancers</i> , 2023, 15, 1316.	1.7	11

#	ARTICLE	IF	CITATIONS
248	Understanding the landscape of immunotherapy in thymic epithelial tumors. <i>Cancer</i> , 2023, 129, 1162-1172.	2.0	1
249	The Changing Landscape of Immunotherapy for Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 335-349.	0.8	2
250	Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
251	Management of Renal Cell Carcinoma With Intra-atrial Tumour Thrombus: A Case Report. <i>Cureus</i> , 2023, , .	0.2	0
252	Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario. <i>Cancer Treatment Reviews</i> , 2023, 115, 102528.	3.4	5
253	Differential Prognostic Value of Extrarenal Involvement in Patients With Non-Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e279-e285.e1.	0.9	0
254	Immunotherapy in Urological, Gynecological and Gastrointestinal Cancers “ Current Landscape. <i>Praxis</i> , 2023, 112, 149-155.	0.2	1
255	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
256	Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions. <i>Current Oncology Reports</i> , 2023, 25, 511-520.	1.8	4
257	Treatment strategies for clear cell renal cell carcinoma: Past, present and future. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	6
258	Top advances of the year: Precision oncology. <i>Cancer</i> , 2023, 129, 1634-1642.	2.0	1
259	Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?. <i>Journal of Clinical Oncology</i> , 2023, 41, 2713-2717.	0.8	10
260	Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava. <i>Cancers</i> , 2023, 15, 1981.	1.7	2
261	The role of stereotactic ablative body radiotherapy in renal cell carcinoma: focus on oligometastatic and oligoprogressive disease. <i>Minerva Urology and Nephrology</i> , 2023, 75, .	1.3	0
262	Multiparametric MRI of Solid Renal Masses: Principles and Applications of Advanced Quantitative and Functional Methods for Tumor Diagnosis and Characterization. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 342-359.	1.9	4
263	Immune checkpoint therapy“current perspectives and future directions. <i>Cell</i> , 2023, 186, 1652-1669.	13.5	114
264	Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2023, 84, 166-175.	0.9	7
265	Predicting the recurrence risk of renal cell carcinoma after nephrectomy: potential role of CT-radiomics for adjuvant treatment decisions. <i>European Radiology</i> , 2023, 33, 5840-5850.	2.3	3

#	ARTICLE	IF	CITATIONS
266	NeoAdjuvant pembrolizumab and Stereotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. Contemporary Clinical Trials Communications, 2023, 33, 101145.	0.5	1
299	From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology, 0, , .	1.9	2
305	Immune-checkpoint inhibition for resectable non-small-cell lung cancer – opportunities and challenges. Nature Reviews Clinical Oncology, 2023, 20, 664-677.	12.5	17
306	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 13477-13494.	1.2	2
330	Management of Metastatic Renal Cell Carcinoma. , 2023, , 41-52.		0
331	Adjuvant Treatment and Follow-Up of Clinically Localized Renal Cell Carcinoma. , 2023, , 53-70.		0
332	Management of Localized and Locally Advanced RCC. , 2023, , 27-39.		0
335	Case Report: Prolonged remission of metastatic cisplatin-refractory nasopharyngeal carcinoma with Pembrolizumab. Frontiers in Oncology, 0, 13, .	1.3	0
340	Management of Renal Cell Carcinoma with IVC Thrombus, Nodal Involvement, and T4 Disease. , 2023, , 143-181.		0
341	Integration of Palliative Care into the Renal Cancer Treatment Paradigm. , 2023, , 399-414.		0
342	Adjuvant Therapies in Renal Cell Carcinoma. , 2023, , 183-194.		0
357	Current status and future perspective of immunotherapy for renal cell carcinoma. International Journal of Clinical Oncology, 0, , .	1.0	0
381	Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma. , 2024, 3, .		0